What is ONC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 20.67B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ONC?

P/E (TTM) is 65.77 and 52-week range is ¥205.51 to ¥319.24 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ONC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ONC?

The company profile lists revenue (TTM) near $3.15B, net income (TTM) near $314M, EPS (TTM) near ¥2.80 when available from the market-data feed. Figures are informational and may lag live markets.

Does ONC show a dividend on Chartloom?

The overview lists dividend per share (TTM) near ¥0.24, yield near 0.12% when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is BeOne Medicines AG based, and what identifiers does Chartloom list?

The company context section lists headquarters in Basel, Basel-Stadt, CH, 113.1M shares outstanding, ISIN CNE100005XT6 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

BeOne Medicines AG

$ONC

Health Care · Biotechnology

Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,825 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Employees

11,825

Website

beonemedicines.com/

IPO

2016-03-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

SHANGHAI STOCK EXCHANGE

ISIN

CNE100005XT6

Headquarters

Basel, Basel-Stadt, CH

Shares outstanding

113.1M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

34.37%

Browse other companiesFree AI scores and summaries for more stocks